The alkylating chemotherapeutic agent temozolomide (TMZ) has been shown to prolong survival in patients with glioblastoma (GBM) and metastatic melanoma; however, patients with these diseases treated with TMZ possess a median survival of Ͻ 15 months. 1,2 Novel approaches are required to treat these devastating malignancies, and the exquisite specificity inherent to immunotherapy makes it an appealing option.
Introduction
The alkylating chemotherapeutic agent temozolomide (TMZ) has been shown to prolong survival in patients with glioblastoma (GBM) and metastatic melanoma; however, patients with these diseases treated with TMZ possess a median survival of Ͻ 15 months. 1, 2 Novel approaches are required to treat these devastating malignancies, and the exquisite specificity inherent to immunotherapy makes it an appealing option.
Despite the potential of cancer immunotherapy, limited success has been achieved within this field due in large part to difficulties in generating appropriate numbers of high-avidity and persistent antitumor T cells. [3] [4] [5] A recent and profound advance in immunotherapy is the use of lymphopenia to augment antitumor immunity through adoptive cellular therapy. [6] [7] [8] Lymphodepletion induces homeostatic proliferation, enabling adoptively transferred activated T cells to become disproportionately overrepresented in the regenerating population and persist for months at high precursor frequencies. [9] [10] [11] [12] Recent studies have primarily examined the lymphodepletive properties of total body irradiation (TBI), and although informative, TBI is not routinely used therapeutically and has a limited clinical context. In contrast, lymphopenia resulting from various standard-of-care chemotherapies, although generally considered an undesirable but inevitable side effect of treatment, could provide a clinically significant means to augment immunotherapy.
TMZ is generally considered an immunosuppressive agent that induces lymphopenia in humans and patients receiving TMZ are routinely given prophylaxis to prevent the development of opportunistic infections. [13] [14] [15] [16] Low-dose TMZ has been shown to enhance "cross-priming" against tumor-derived antigens in experimental mice 17 ; however, the direct effects of lymphodepletive doses of TMZ on vaccine-induced immunologic responses and regulatory T cells (T Regs ) has not been examined.
Here, we report that lymphodepletive TMZ strongly augments vaccine-induced immune responses in a dose-dependent manner and that combinatorial vaccination and lymphopenia in mice bearing established B16/F10.9-OVA tumors significantly impaired malignant growth despite an increase in the frequency of CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs . This TMZ-induced enhancement of immunity is dramatically augmented when combined with anti-IL-2R␣ monoclonal antibody (mAb)-mediated depletion of CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs , whereas identical treatment in normal mice impaired vaccine-induced effector responses. Anti-IL-2 receptor ␣ (IL-2R␣) mAb treatment can suppress activated T cells in normal mice 18 and can suppress vaccine-induced immune responses in patients with metastatic melanoma. 19 However, to our knowledge, this is the first demonstration that the lymphopenic environment differentially impacts whether vaccination can be successfully combined with systemic antibody-mediated T Reg depletion in the treatment of established tumors. To determine whether these findings could be translated in humans, TMZ-treated patients with GBM received combinatorial IL-2R␣ blockade using daclizumab (Hoffman-La Roche) and DC vaccination targeting the human cytomegalovirus (CMV) antigen pp65 that we and others have shown to be expressed in a high proportion of GBM tumors. [20] [21] [22] [23] [24] T Reg frequencies in GBM patients were also significantly depleted and vaccine-induced antitumor immune responses were simultaneously enhanced. Cumulative preclinical and clinical results indicate that synergistic lymphopenia with concomitant IL-2R␣ blockade selectively depletes T Regs and potentiates antitumor immunotherapy in both mice and humans.
Methods

Mice and tumor cell lines
C57BL/6J and OT-I transgenic mice were from The Jackson Laboratory and were bred under pathogen-free conditions at Duke University Medical Center. All animal experiments were performed according to Duke University Institutional Animal Care and Use Committee-approved protocols. B16F10.9-OVA 25 was a gift from Dr Smita Nair (Duke University Medical Center).
Peripheral blood draws and complete blood counts
Fifty to 100 L of blood was collected into heparinized tubes by retroorbital bleeding for complete blood counts (CBCs) and flow cytometric analysis. CBCs were performed on a VetScan HM5 hematology analyzer (Abaxis).
Isolation of murine T cells and flow cytometry
Murine T cells were isolated and stained for FACS analysis using protocols established previously in our laboratory. 26 For analysis of peripheral blood, whole blood was incubated with antibodies in the dark for 15 minutes at room temperature before lysing red blood cells (RBCs) with 1ϫ ammonium chloride lysing solution (BD Biosciences), cells were washed and resuspended in 2% paraformaldehyde. All samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Antibodies and CFSE staining
Antibodies to CD3 (145-2C11), CD4 (L3T4), CD8 (53-6.7), CD16/32 (2.4G2), CD25 (7D4), and isotype controls were from BD Biosciences Pharmingen. Anti-Foxp3 (FJK-16s) was obtained from eBioscience. IL-2R␣ mAb (PC61) ascites for in vivo administration were obtained from Accurate Chemical & Scientific. For CFSE labeling, harvested splenocytes were resuspended at 2 ϫ 10 7 cells/mL and incubated in PBS with 2% FCS and 20nM CFSE (Invitrogen) for 6 minutes at 37°C. Cells were washed, resuspended in PBS and 2% FBS, incubated at 37°C for 10 minutes, and washed again before use.
Cytometric bead array
We collected 50 L of peripheral blood from mice and transferred the blood to a 96-well plate. RBCs were lysed with 1ϫ lysing buffer (BD Pharm Lyse; BD Biosciences), and cells were washed twice and stimulated with 100 g/mL ovalbumin (OVA) peptide in AIM-5 media with 5% FBS. Cells were incubated at 37°C with 5% CO 2 , and supernatant was collected after 48 hours. We then mixed 50 L of culture supernatant with 50 L of capture beads and 50 L of detection reagent (CBA mouse inflammation kit; BD Biosciences) and incubated the sample for 2 hours at room temperature. Next, the sample was washed and analyzed by flow cytometry per the manufacturer's instructions.
MILLIPLEX cytokine panel
Peripheral blood was collected from mice 72 hours after the cessation of TMZ treatment. Plasma was derived and IL-2, IL-15, and IL-7 cytokine levels were determined (MILLIPLEX MAP mouse cytokine/chemokine kit protocol; Millipore) following the manufacturer's instructions.
T-cell suppression and proliferation assays
Cells were cultured and assayed as described previously. 26 Generation of murine bone marrow-derived DCs, electroporation, and phenotyping Bone marrow-derived DCs were generated from C57BL/6 mice as described previously using recombinant murine GM-CSF and IL-4. On day 8, nonadherent cells were harvested for RNA electroporation and suspended in Opti-MEM (Invitrogen) at 2.5 ϫ 10 7 cells/mL. Aliquots (5 ϫ 10 6 ) cell were mixed with 10 g of OVA RNA, loaded into cold 2-mm cuvettes (Bio-Rad Laboratories), electroporated using a BTX model ECM 830 square wave electroporation system at 300 V for 500 s, and replated in 60-mm culture dishes. On day 9, nonadherent cells were harvested for vaccination or in vitro stimulation.
Tumor implantation
B16/F10.9-OVA cells were grown in DMEM, 10% FCS, and 2mM L-glutamine. For tumor implantation, 1 ϫ 10 5 cells in 100 L of PBS were injected subcutaneously in the flank of C57BL/6 mice 3 days before treatment with TMZ. After 7 days, site of implantation was monitored daily for tumor growth, and tumor size was measured every 2-3 days. The volume of the tumor (cubic millimeters) was calculated by the formula (length ϫ width 2 ϫ 0.52). Mice were killed when the tumor size reached 2 cm in any direction.
Preclinical temozolomide treatment, OT-I transfer, vaccination, and PC61 administration C57BL/6 mice were injected intraperitoneally with TMZ (Temodar; Schering Plough) dissolved in a fresh solution of 85% saline and 15% DMSO; mice were weighed and injected intraperitoneally with a calculated single dose (milligrams per kilogram) or consecutive daily doses for 5 days (milligrams per kilogram per 5 days) as indicated. Standard-of-care TMZ (200 mg/m 2 ) for a 65-kg, 60-inch human is equivalent to a murine dose of 66.31 mg/kg. 27, 28 Twenty-four to 48 hours after TMZ treatment, lymphodepleted mice received splenocytes from CD8 ϩ OVA-specific TCR transgenic mice (OT-I mice) and normal C57BL/6 donor mice mixed at a 1:1 ratio (2 ϫ 10 7 cells in total). Concomitant with lymphocyte infusion, mice were vaccinated intradermally with 5 ϫ 10 5 OVA-loaded DCs or intradermally with 100 g of OVA protein (Sigma-Aldrich) and 100g of OVA class I peptide (sequence Ser-Ile-Ile-sn-PheGlu-Lys-Leu [SIINFEKL]; American Peptide) in 10% DMSO with an equal volume of complete Freund adjuvant (100 L/mouse; Difco); for repeat peptide vaccinations incomplete Freund adjuvant was used. For mAb-mediated blockade of IL-2R␣, mice received 300 L (0.62 mg/mL) PC61 intraperitoneally simultaneous with vaccination.
Patient selection and clinical protocol
Adults with a newly diagnosed, single lesion WHO grade 4 GBM who had gross total resection, Karnofsky Performance Scale score Ն 80, and a Curran Group status of I-IV at the time of enrollment were eligible for enrollment. Postresection, patients received 6-7 weeks of conformal external beam radiotherapy with concurrent TMZ at 75 mg/m 2 . Patients with radiographic progression after external beam radiotherapy (Ͼ 20% increase in enhancement in comparison to postsurgical magnetic resonance imaging) did not receive vaccine. The trial design and informed consent were approved by the US Food and Drug Administration and the Duke University Medical Center Institutional Review Board.
Patients received adjuvant TMZ at 200 mg/m 2 for 5 days of a 28-day cycle and 3 biweekly DC vaccines (2 ϫ 10 7 DCs administered intradermally within 10 cm of the inguinal ligament) starting on day 21 of the first TMZ cycle. At vaccine 1, daclizumab was administered intravenously at a dose of 1 mg/kg. After daclizumab administration, patients received an autologous lymphocyte transfer intravenously at a dose of 3 ϫ 10 7 cells/kg.
The fourth and final vaccine was given on day 21 of the second TMZ cycle. Patients without tumor progression continued to receive monthly TMZ cycles for target of 6 to 12 cycles as tolerated.
Patients were monitored bimonthly by magnetic resonance imaging. Progressive disease was defined radiographically according to the Macdonald criteria 29 or by the development of a new contrast-enhancing lesion more than 1 cm in diameter. Adverse events were defined according to the National Cancer Institute's Common Toxicity Criteria Version 2.0.
Production of pp65-LAMP/A64 mRNA
The 1.932-kb pp65 full-length cDNA insert was obtained from Dr Bill Britt (University of Alabama-Birmingham). The lysosome-associated membrane protein (LAMP)-targeting sequence ligated to pSP73/gp96ss/A64/ Not was obtained from Dr Eli Gilboa (Miller School of Medicine, University of Miami). The PCR-generated pp65 full-length cDNA with SfiI ends was cloned into the vector pSP73/gp96ssLAMP/A64/Not Template DNA for in vitro transcription was linearized with restriction enzyme SpeI and purified using QIAquick PCR purification kit (QIAGEN). The gp96ss/ pp65-LAMP/A64/mRNA was synthesized using the T7 mMessage mMachine RNA transcription kit (Ambion) according to the manufacturer's instructions. RNA was purified using RNeasy purification kit (Promega) according to the manufacturer's instructions.
In vitro generation of DCs
DCs were generated using the method of Romani et al 30 and frozen in 80% human AB serum (HABS; Valley Biomedical) 10% DMSO (Bioniche , and then CBCs were compared with untreated controls (n ϭ 5). Total lymphocyte counts in peripheral blood were monitored over the course of 28 days; a representative experiment shown (n ϭ 3). Postlymphodepletion values were evaluated for statistical significance (day 2): untreated vs 200 mg/kg TMZ, 60 mg/kg/5 day TMZ, and TBI, P Ͻ .0001 for all comparisons; and TBI vs 200 mg/kg TMZ and 60 mg/kg/5 day TMZ, P ϭ .2042 and P ϭ .0168, respectively. (B-C) The frequency and absolute number of CD4 ϩ and CD8 ϩ T cells and CD4 ϩ CD25 ϩ Foxp3 ϩ TRegs in the peripheral blood of untreated (n ϭ 5), lymphodepletive TMZ-treated (n ϭ 5), and TMZ-lymphodepleted mice who also received OT-I transfer (n ϭ 5) were monitored by FACS analysis 1 week after TMZ administration (frequency CD4 ϩ , *P ϭ .0396 and **P ϭ .0216; frequency TRegs, *P ϭ .0006 and **P ϭ .0019). For FACS analysis of all murine T-cell populations (supplemental Figure 11 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article), total lymphocytes were first gated by side scatter and forward scatter. For CD4 ϩ and CD8 ϩ T-cell selection, total CD3 ϩ T cells were selected from the lymphocyte gate by displaying side scatter by CD3 ϩ . CD4 ϩ or CD8 ϩ T cells were selected from the CD3 ϩ T-cell population by displaying CD4 ϩ by CD8 ϩ and gating the desired population. For TRegs, lymphocytes were first gated by forward and side scatter, and from this gate CD4 ϩ T cells were selected from side scatter. CD4 ϩ T cells were displayed by CD25 versus Foxp3. For CD4 ϩ CD25 ϩ Foxp3 ϩ TRegs, double-positive cells were selected and for CD4 ϩ Foxp3 ϩ TRegs all Foxp3 ϩ T cells were selected. Representative experiments are shown; all experiments performed in at least triplicate. (D) C57BL/6 mice were treated with 200 mg/kg single dose TMZ or 60 mg/kg/5day. Three days after the completion of TMZ treatment, CD4 ϩ CD25 Ϫ responder T cells and CD4 ϩ CD25 ϩ TRegs were isolated and cultured for 3 days in the presence of ␣-CD3e beads (all wells in triplicate). Proliferation was assessed after a 16-hour incubation with [ 3 H]thymidine. (E) To determine the ratio of effector cells to TRegs, the absolute number of peripheral blood CD8 ϩ cells was divided by the absolute number of peripheral blood TRegs (n ϭ 5/cohort), ratios from representative experiments (B-C). *P ϭ .0354.
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Analysis of human PBMCs
Human samples were obtained from individuals who had given written and informed consent, and peripheral blood mononuclear cells (PBMCs) were obtained and stained for FACS analysis as described previously. 31, 32 To determine the absolute number of T Regs and CD4 ϩ T cells, the frequency of these populations as established by FACS analysis was multiplied by the absolute number lymphocytes as determined by CBC, white blood cell frequencies, and lymphocyte frequencies from the Duke University Clinical Laboratory.
Statistical analysis
Unless otherwise stated, an unpaired 2-tailed Student t test was used to determine statistical significance. Two-way and 3-way ANOVA with interaction was used to assess the effects of temozolomide, anti-IL-2R␣ mAb, and vaccine on various immune measures and tumor volume. Parsimonious models were created by backward elimination. Pearson correlation was used to assess the association between TMZ dose and the levels of OVA-specific T cells. P values Ͻ .05 were considered significant. All figures shown are of representative experiments.
Results
Temozolomide as a lymphodepletive regimen
To determine a lymphodepletive dose (Ͻ 2000 cells/L of peripheral blood) of TMZ in our murine model, mice were injected with increasing single doses (50-400 mg/kg) or multiday doses (20-80 mg/kg/5 days) of TMZ along with a separate cohort receiving lymphodepletive TBI (5 Gy; supplemental Table 1 ). Both 200 mg/kg TMZ single dose and 60 mg/kg/day TMZ for 5 days induced lymphopenia similarly to TBI ( Figure  1A) , significantly reduced the absolute numbers of CD4 ϩ and CD8 ϩ T cells (supplemental Figure 1) , and were considered lymphodepletive regimens.
-cell frequencies are elevated after lymphodepletive TMZ
To investigate the recovery from TMZ-induced lymphodepletion and to establish a model for evaluation of antigen-specific T cells, TMZ-treated mice were given an adoptive lymphocyte transfer of 2 ϫ 10 7 naive splenocytes consisting of an equal proportion of OVA TCR transgenic splenocytes (OT-I) and wild-type C57BL/6 Mice were given increasing doses of TMZ before vaccination as described in "Preclinical temozolomide treatment, OT-I transfer, vaccination and PC61 administration." The frequency and absolute number of OVA-specific T cells were monitored in peripheral blood using an OVA-specific tetramer and anti-CD8 mAb. For all murine tetramer FACS analyses, cells were gated with the following strategy: total lymphocytes were gated from forward and side scatter, CD8 ϩ T cells were selected from the lymphocyte gate, and the population of OVA ϩ T cells was selected from total CD8 ϩ lymphocytes (supplemental Figure 11) . No vaccine, n ϭ 3; untreated, n ϭ 5; 50 mg/kg TMZ, n ϭ 5; 75 mg/kg TMZ, n ϭ 5; and 200 mg/kg TMZ, n ϭ 5. Increasing TMZ dose was associated with both increasing frequencies of OVA-specific T cells (Pearson correlation ϭ 0.69; P ϭ .0008) and increasing absolute numbers of OVA-specific T cells (Pearson correlation ϭ 0.54; P ϭ .014). This experiment was repeated twice with similar results. (C) Untreated (n ϭ 3), TMZ-lymphodepleted (n ϭ 3), or 5-Gy TBI-treated (n ϭ 3) C57BL/6 mice received CFSE-labeled OT-I T cells and OVA vaccination. Proliferation of CD4 ϩ , CD8 ϩ , and CD8 ϩ OVA ϩ T cells was monitored by CFSE dilution. Representative FACS plots are shown.
splenocytes. The absolute numbers of all assessed T-cell compartments in TMZ-treated mice were not altered by the addition of OT-I cells ( Figure 1B-C) , with mice exhibiting similar counts of CD4 ϩ , CD8 ϩ ( Figure 1B ), CD4 ϩ Foxp3 Ϫ (supplemental Figure 2) , and CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs ( Figure 1C ). The frequencies of CD4 ϩ T cells and T Regs were significantly increased by TMZ treatment, with the proportion of T Regs doubling after TMZ (P ϭ .0006) or after TMZ ϩ OT-I (P ϭ .0019). This elevation in CD4 ϩ T-cell frequency is attributable to changes in the T Reg compartment, because analysis of CD4 ϩ Foxp3 Ϫ T cells showed no significant increase in frequency after TMZ or TMZ ϩ OT-I (supplemental Figure 2) . The absolute numbers of CD4 ϩ and CD8 ϩ T cells remained depressed 1 week after TMZ ( Figure 1B) ; however, the absolute numbers of T Regs were unchanged from untreated mice ( Figure 1C ). To determine whether T Regs were resistant to TMZmediated depletion or whether they simply recovered from depletion faster, the absolute numbers of CD4 ϩ T cells and T Regs were examined early after TMZ treatment. Both T-cell subsets were significantly reduced (supplemental Figure 3A) with similar levels of depletion (supplemental Figure 3B) , indicating that T Regs rebound faster than CD4 ϩ T cells. Importantly, T Regs isolated after TMZ treatment were equivalently immunosuppressive in vitro, suggesting that lymphodepletive TMZ has no impact on the suppressive function of CD4 ϩ Foxp3 ϩ T Regs ( Figure 1D ).
We also evaluated the impact of TMZ and TMZ ϩ OT-I on the effector T cell to T Reg (T Eff :T Reg ) ratio, defined as the ratio of the absolute number of peripheral blood CD8 ϩ T cells to T Regs , because decreased T Eff :T Reg ratios have been associated with reduced immune responses and diminished antitumor efficacy after immunotherapy. 33 Although there was a small increase in the T Eff :T Reg ratio in the TMZ ϩ OT-I cohort in comparison with TMZ alone, the T Eff :T Reg ratios in both the TMZ and TMZ ϩ OT-I cohorts were reduced in comparison with untreated controls. Therefore, lymphodepletive TMZ could impair antitumor immunity due to both a decrease in circulating lymphocytes and because of an elevated proportion of T Regs ( Figure 1E ).
TMZ-mediated lymphodepletion enhances vaccine-induced immune responses despite increased frequencies of T Regs
Because TMZ quickly increases the proportion of T Regs , and because T Regs have been shown to suppress lymphodepletioninduced homeostatic proliferation and vaccine-stimulated immunity, 34, 35 we next assessed the impact of TMZ treatment on vaccine-induced immunologic responses. C57BL/6 mice were given escalating doses of TMZ before OVA immunization. We found that the frequency and absolute number of vaccine-induced immunologic responses were increased in a dose-dependent manner in mice previously treated with TMZ ( Figure 2A , Pearson correlation ϭ 0.69, P ϭ .0008; Figure 2B , Pearson correlation ϭ 0.54, P ϭ .014) and that this increase in T-cell expansion was observed in mice after receiving a single dose of TMZ or a multiday regimen of TMZ (supplemental Figure 4) . These results indicate that TMZ-induced lymphopenia leads to increased vaccineinduced immunologic responses despite increased T Reg proportions. To determine whether TMZ induces homeostatic proliferative responses in mice and to evaluate the relative kinetics of lymphopenia-induced homeostatic proliferation versus vaccineinduced proliferation, mice received CFSE-labeled OT-I T cells after lymphodepletive TMZ or 5 Gy of TBI and before vaccination. Proliferation was assessed by flow cytometric analysis of CFSE dilution 1 week after vaccination ( Figure 2C ). In both TMZ-and TBI-treated animals, proliferation was observed in the overall CD8 ϩ and CD4 ϩ compartments, with greater cell division (CFSE loss) seen in CD8 ϩ T cells, demonstrating that the lymphodepletive environments induced by 5 Gy of TBI and TMZ induce similar levels of lymphopenia-induced homeostatic proliferation. To examine the proliferation of vaccine-induced T cells, CFSE dilution was examined within the OVA tetramer-positive CD8 ϩ T-cell population. Vaccine-induced OVA-specific T cells, however, proliferated extensively, with Ͼ 94% of the cells exhibiting almost a complete loss of CFSE label (Figure 2C bottom panel) . The vaccine-induced T cells proliferated to a similar extent in lymphopenic and normal (A-C) Untreated or TMZlymphodepleted C57BL/6 mice received OVA vaccination with or without concomitant ␣IL-2R␣ mAb treatment (n ϭ 5/group). One week after mAb administration and vaccination, mice were bled and CD4 ϩ CD25 ϩ Foxp3 ϩ TReg levels in the peripheral blood were assessed by FACS analysis. Experiments performed in at least triplicate with similar results. (A-B) For frequency TRegs: *P ϭ .0154, **P ϭ .0027, and ***P ϭ .0001. By 2-way ANOVA with interaction, the magnitude of effect of anti-IL-2R␣ mAb was greater among TMZ-treated mice as opposed to mice not treated with TMZ (P ϭ .0024). For absolute number of TRegs, *P ϭ .0025. (C) In the untreated and TMZ-treated cohorts, the percentage depletion of CD4 ϩ CD25 ϩ Foxp3 ϩ TRegs after ␣IL-2R␣ mAb administration was determined from the absolute number of TRegs after ␣IL-2R␣ mAb treatment in comparison with the absolute number of TRegs in the cohort that did not receive IL-2R␣ blockade.
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Anti-IL-2R␣ mAb administration synergizes with lymphopenia to deplete T Regs and potentiate immune responses
Although it has been proposed that lymphopenia augments immunotherapeutic protocols in part via depletion of inhibitory T Regs , our results demonstrate that immune responses are strongly potentiated after lymphodepletive TMZ despite an early increase in the frequency of functional CD4 ϩ CD25 ϩ Foxp3 ϩ regulatory T cells and a decreased T Eff :T Reg ratio ( Figure 1C-E) . These data suggest that complementary T Reg blockade strategies may synergize well with TMZ-induced lymphodepletion to further enhance immunotherapeutic antitumor immunity. To assess whether depletion or inhibition of T Regs in the context of TMZ treatment would further amplify vaccine-induced immunity, we examined the effect of anti-IL-2R␣ mAb administration on T Regs in normal hosts and during TMZ-mediated lymphopenia. Untreated or lymphopenic mice were injected intraperitoneally with 10 mg/kg of the anti-IL-2R␣ mAb PC61 concomitant with vaccination; peripheral blood T Reg levels were assessed 1 week later. In both untreated (P ϭ .0154) and TMZ-treated (P ϭ .0001) mice, anti-IL-2R␣ mAb administration caused a significant decrease in the frequency of remaining CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs ( Figure 3A) , and the absolute number was significantly depleted by anti-IL-2R␣ blockade in TMZtreated mice (P ϭ .0025; Figure 3B ). In addition, the percentage of depletion induced by anti-IL-2R␣ mAb administration was not significantly different between TMZ-treated mice and controls ( Figure 3C ). Kohm et al 36 have alternatively shown that in vivo injection of anti-IL-2R␣ mAb causes down-regulation or shedding of IL-2R␣ on T Regs rather than T Reg depletion. To confirm that our anti-IL-2R␣ mAb-induced reduction of CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs was not from IL-2R␣ expression loss, we examined the impact of anti-IL-2R␣ mAb administration on CD4 ϩ Foxp3 ϩ T Regs . Similar to our data on CD4 ϩ CD25 ϩ Foxp3 ϩ cells, the frequency and absolute number of CD4 ϩ Foxp3 ϩ T Regs 1 week after PC61 and vaccination were reduced in both untreated and TMZ-treated cohorts, and the percentage of depletion induced by IL-2R␣ blockade was not significantly different between untreated and TMZ ϩ ␣IL-2R␣ had a significant effect on IL-2 production (P ϭ .0005), and TMZ alone had a significant effect on IL-7 production (P ϭ .0001). Asterisks denote significance (P Ͻ .05) versus untreated. (E) Memory recall responses were evaluated 5 weeks after vaccination in treated mice by measurement of IFN␥ secretion in peripheral blood lymphocytes using CBA. *P ϭ .0082 and **P ϭ .0198 by unpaired t test. Figure 5A-C) . However, because work from our laboratory 26 has shown that CD25 Ϫ T Regs isolated after anti-IL-2R␣ mAb administration are no longer functionally suppressive, we have continued to examine CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs as our primary population of interest.
TMZ-treated mice (supplemental
Although T Regs have been shown to be particularly dependent on the expression of IL-2R␣ and consequent IL-2 signaling, it is important to note that activated T cells also transiently express the high-affinity IL-2R. Therefore, it is possible that PC61 administration may impair vaccine-induced antigen-driven effector responses in addition to depleting T Regs . To investigate this possibility, we analyzed the kinetics of OT-I expansion in untreated and TMZlymphodepleted hosts after simultaneous OVA vaccination and PC61 administration (Figure 4A-B) . The vaccine-driven expansion of OT-I cells in untreated animals was effectively abrogated in the presence of IL-2R␣ blockade. This corroborates the work of others showing the dependence of activated T cells on IL-2 signaling for fully realized immunologic responses and the impairment of these responses by anti-IL-2R␣ blockade. 18, 19 In sharp contrast, the dramatic expansion of OT-I cells engendered by the lymphopenic environment was not abolished during anti-IL-2R␣ mAb administration but was increased in both magnitude and duration over the observed period of time. Four weeks after immunization, the percentage of OT-I cells increased from 0.3% among untreated animals to 21% among TMZ only-treated animals (P ϭ .0004). TMZ-treated animals receiving PC61 and vaccine had a 2-fold increase in the percentage of OT-I cells in comparison with vaccinated mice receiving TMZ only (P ϭ .036) and greater than a 100-fold increase over untreated and vaccinated animals (P ϭ .0009). Importantly, this led to increases in the T Eff :T Reg ratio for both CD4 ϩ CD25 ϩ Foxp3 ϩ and CD4 ϩ Foxp3 ϩ T Reg populations in TMZ-treated animals ( Figure 4C ; supplemental Figure 6 ). These animals did not exhibit any signs of autoimmune toxicity during the observation period of 60 days (data not shown). Therefore, in the context of a lymphopenic setting, but not in a normal environment, administration of anti-IL-2R␣ antibodies allows for the selective depletion of T Regs and enhancement of vaccinestimulated effector T cells.
To investigate the impact of TMZ treatment on lymphocyte homeostatic cytokines in our model of lymphodepletive TMZ, we examined the levels of IL-2, IL-7, and IL-15 in the plasma of untreated or TMZ-lymphodepleted mice treated with or without anti-IL-2R␣ mAb ( Figure 4D ). Plasma levels of IL-15 were unchanged; however, IL-7 levels were increased after TMZ treatment (analysis of variance, P ϭ .0001) and IL-2 levels were increased after the combination of TMZ and anti-IL-2R␣ mAb administration (analysis of variance with interaction, P ϭ .0005). In vitro anti-IL-2R␣ mAb administration has been shown previously to liberate IL-2, which may account for the up-regulation of IL-2 after lymphodepletion and IL-2R␣ blockade. 37 Therefore, the data indicate that in the context of TMZ-induced lymphopenia, the selective depletion of T Regs via IL-2R␣ blockade simultaneous with vaccine-induced effector T-cell expansion may be mediated by an early surge in IL-7.
Previous studies also have demonstrated that although IL-2 signaling is dispensable during primary responses, it is essential for normal immunologic memory responses, 38 thus prompting the possibility that immunologic memory responses may be significantly impaired in mice receiving PC61 treatment during vaccination. To investigate this possibility, the cytokine recall responses (IFN␥) of OVA-specific T cells were evaluated 5 weeks after vaccination in untreated and TMZ-treated mice. IFN␥ responses were diminished in normal mice receiving IL-2R␣ blockade but enhanced in mice receiving IL-2R␣ mAb treatment during recovery from TMZ ( Figure 4E ), suggesting that the selective depletion of T Regs in TMZ-treated mice led to enhanced primary and memory T-cell responses.
IL-2R␣ mAb blockade during lymphopenia effectively enhances antitumor efficacy in an established model of tumorigenesis
We and others have observed that T Reg depletion via antibodymediated blockade of IL-2R␣ enhances antitumor efficacy most effectively in prophylactic rather than therapeutic settings, 26, 33, 39 potentially because of the simultaneous inhibition of physiologic or vaccine-induced antitumor immune responses by anti-IL-2R␣ mAbs when used against established tumors. 18 To determine whether PC61 administration in the context of recovery from TMZ-induced lymphopenia could mediate significant improvements in therapeutic antitumor immunity, we assessed the efficacy of OVA vaccination on established B16/F10.9-OVA tumors ( Figure  5 ; supplemental Figure 7 ). Mice were subcutaneously inoculated with tumor cells 3 days before lymphodepletive TMZ treatment and 1 week before initial immunization and PC61 administration, with additional vaccinations occurring on days 12 and 17 after tumor implantation. Mice were assessed for tumor burden throughout the course of the experiment. On day 22 after implantation, tumors reached maximal size in untreated mice, and the experiment was terminated for end point evaluation. TMZ in combination with vaccine significantly reduced the tumor volume (P ϭ .0015), and the addition of PC61 only in the context of TMZ and vaccine provided a further significant reduction in tumor volume (P ϭ .0035; Figure 5 ; supplemental Figure 7 ). TMZ treatment alone or vaccine alone did not impair tumor growth in comparison with untreated tumor-bearing mice (P ϭ .1922 and P ϭ .3343, respectively; supplemental Figure  7) . Administration of PC61 alone in untreated or TMZ-treated mice had no effect on tumorigenesis (P ϭ .3343 and P ϭ .5515, respectively; supplemental Figure 7 ) in comparison with controls, indicating that the systemic depletion of T Regs in normal or Figure 5 . Administration of anti-IL-2R␣ mAb during lymphopenia augments vaccine-induced antitumor efficacy. B16/F10.9-OVA tumors were implanted subcutaneously in C57BL/6 mice, and TMZ was administered 3 days later. One week after implantation, cohorts of mice received vaccination with or without ␣IL-2R␣ mAb administration. Mice were additionally vaccinated on days 12 and 17 after implantation (n ϭ 8 per group). Statistical significance by unpaired t test on day 22 (maximal tumor burden in untreated mice): untreated ϩ vaccine versus TMZ ϩ vaccine, P ϭ .0729; untreated ϩ vaccine ϩ ␣IL-2R␣ mAb versus TMZ ϩ vaccine ϩ ␣IL-2R␣ mAb, P ϭ .0024; and TMZ ϩ vaccine versus TMZ ϩ vaccine ϩ ␣IL-2R␣ mAb, P ϭ .0268).
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For personal use only. on July 15, 2017. by guest www.bloodjournal.org From lymphopenic mice with established tumor did not impair tumor growth. These results offer a striking parallel to our immune response data and indicate that IL-2R␣ blockade during lymphopenia uniquely enables the selective depletion of T Regs to augment vaccine-induced effector T-cell function and potentiate antitumor immunotherapy in an established model of tumorigenesis.
Impact of anti-IL-2R␣ mAb administration in TMZ-treated patients with GBM receiving targeted immunotherapy
Because of these preclinical findings, we assessed the potential of a single intravenous dose of a humanized anti-IL-2R␣ mAb (daclizumab) to reduce or eliminate T Regs and augment vaccine-induced antitumor immunity in a pilot study of patients with newly diagnosed GBM receiving adjuvant TMZ therapy ("REGULATE" Protocol, Food and Drug Administration IND-BB-12839; Duke Institutional Review Board Protocol 0581). Six patients were treated in this pilot study (demographic data shown in Table 1 ). On day 21 Ϯ 2 of the first TMZ cycle (during lymphocyte nadirs), patients received 1 mg/kg daclizumab, adoptive transfer of 3 ϫ 10 7 /kg naive lymphocytes harvested during leukapheresis to serve as a responder population to vaccination, and a vaccine consisting of 2 ϫ 10 7 DCs electroporated with CMV pp65 RNA.
Patients also received 2 biweekly RNA-pulsed DC vaccinations and a fourth vaccine on day 21 Ϯ 2 after their second TMZ cycle. In parallel to our findings in mice, patients displayed a significantly increased frequency of CD4 ϩ CD25 ϩ Foxp3 ϩ T Regs after TMZ treatment ( Figure 6A ; P ϭ .0236). After daclizumab administration, the frequency of T Regs was significantly reduced (P ϭ .0061) in treated patients, with absolute numbers decreasing by ϳ 34% (P ϭ .1494). Examination of CD4 ϩ Foxp3 ϩ T Regs revealed the same trends, with T Reg frequency increased after TMZ (P ϭ .0239) and decreased after daclizumab (P ϭ .0160) and with the absolute number reduced after daclizumab by 25% (P ϭ .3461; supplemental Figure 8 ). The kinetics of T Reg depletion revealed that T Reg levels spiked after the first cycle of TMZ but dropped rapidly after anti-IL-2R␣ treatment (day 0) without returning to baseline over a 50-day period of observation ( Figure 6B ; supplemental Figure 9 ). Importantly, overall CD4 ϩ and CD4 ϩ Foxp3 Ϫ T cells experienced no reduction in absolute number or frequency after daclizumab administration in comparison with post-TMZ levels, indicating that anti-IL-2R␣ mAb administration during TMZ-induced lymphopenia selectively eliminates T Regs , as was observed in our murine studies (supplemental Figure 10) . IL-2R␣ mAb blockade did not prevent our capacity to enhance immunologic responses, because Percentages and absolute numbers of TRegs (CD4 ϩ CD25 ϩ Foxp3 ϩ ) from leukapheresis (pre-TMZ and post-TMZ and daclizumab) and peripheral blood (post-TMZ) samples were determined by CBC counts and FACS analysis. TReg levels from preoperative samples (pre-TMZ, ϳ day Ϫ 100), before initial vaccination and daclizumab (post-TMZ, day 0) and ϳ 7 weeks after vaccination and daclizumab (post-TMZ and daclizumab, day ϳ 50) were assessed. (A) Frequency of TRegs by paired t test, *P ϭ .0236 and **P ϭ .0061. (B) Total CD4 ϩ , CD4 ϩ Foxp3 ϩ , and CD4 ϩ CD25 ϩ Foxp3 ϩ T-cell frequencies from leukapheresis and peripheral blood samples from a representative patient were determined before and after daclizumab administration (day 0). Gating strategies for flow cytometric analyses were as follows and as shown in supplemental Figure 12: (1) For CD4 ϩ T cells, all cells were displayed using forward and side scatter, and the lymphocyte population was selected. Lymphocytes were then displayed by side scatter and CD4 on a dot plot. The CD4 ϩ population was then selected out of this lymphocyte population. (2) For Foxp3 ϩ of CD4 ϩ , an identical gating strategy as described in 1 was used to select CD4 ϩ T cells. The CD4 ϩ T cells were then displayed by dot plot against Foxp3, and all Foxp3 ϩ cells were selected. (3) For CD25 ϩ Foxp3 ϩ of CD4 ϩ , an identical gating strategy as described in (1) was used to select the CD4 ϩ population. The selected CD4 ϩ population was then displayed by dot plot as CD25 versus Foxp3. CD25 and Foxp3 double-positive cells were then selected out of the CD4 ϩ population. Representative FACS plot of pp65-tetramer ϩ CD8 ϩ T cells. Gating strategy: total lymphocytes selected from forward scatter and side scatter display, CD3 ϩ CD8 ϩ T cells selected from total lymphocytes, and pp65 ϩ T cells selected from total CD3 ϩ CD8 ϩ population (supplemental Figure 12) .
we found that 4 of 6 patients displayed an increase in pp65-specific T cells after vaccination with a mean 4-fold increase in tetramerpositive CD8 ϩ T cells (Figure 7) . The administration of daclizumab in combination with DC vaccination was well tolerated without any adverse events associated with immunotherapy, and although clearly not powered for a clinical end point, 4 of 6 patients treated have experienced progression-free survival times exceeding 24 months, warranting further exploration of the safety and efficacy of this treatment strategy in larger clinical trials ( Table 1 ). The cumulative clinical data parallel our preclinical work and strongly suggests that anti-IL-2R␣ mAb treatment in TMZ-treated patients with GBM may enhance vaccine-driven antitumor immunity through a selective reduction in immunosuppressive regulatory T cells.
Discussion
We report that TMZ has lymphopenic side effects that can be potently leveraged to improve immunotherapy as determined by both immune responses and therapeutic antitumor efficacy. We also demonstrate that improved antitumor immunity occurs despite an increased proportion of immunosuppressive T Regs and that the dramatic potentiation of vaccination by TMZ-induced lymphopenia can itself be significantly heightened through the concomitant depletion of T Regs by anti-IL-2R␣ mAb treatment. High-affinity IL-2R antibodies administered during lymphodepletion selectively deplete T Regs to promote vaccine-stimulated immune responses and inhibit malignant growth. Although these results need confirmation in larger patient studies, we demonstrate that anti-IL-2R␣ mAb administration in TMZ-treated patients also selectively depletes regulatory T cells while permitting the expansion of vaccineinduced effector T cells.
The significance of these observations are substantial, suggesting that the treatment of GBM and metastatic melanoma with TMZ provides a clinically relevant therapeutic window that can be manipulated to promote antitumor immunity. Of additional import is that TMZ-induced lymphopenia actually increases regulatory T cells in mice and humans, prompting us to examine the efficacy of tumor vaccination during combinatorial lymphopenia and systemic T Reg depletion. In normal animals, our work and the work of others demonstrates that IL-2R␣ blockade will impair immune activation, probably because of the transitory expression of IL-2R␣ on activated T cells during priming. 18, 19, 40 However, our data demonstrate that although T Regs are depleted or functionally inhibited by anti-IL-2R␣ mAbs during both normal and lymphopenic conditions, it is only during lymphodepletion that anti-IL-2R␣ mAb treatment does not impair immune responses but in fact strongly accentuates them while simultaneously inhibiting suppressive T Regs .
Several mechanisms may account for the selective depletion of T Regs by anti-IL-2R␣ mAbs during lymphopenia. In our model of lymphodepletive TMZ, early elevation of IL-7 cytokine levels ( Figure 4D ) may permit effector T cells to expand in the absence of IL-2-mediated signaling, whereas T Regs will remain dependent on IL-2 for survival and proliferation. Alternatively, an indirect mechanism of daclizumab suppression mediated through CD56 bright regulatory natural killer cells may be bypassed through the depletion of these cells during lymphodepletive regimens. 41 Importantly, the above-mentioned hypotheses are not dependent on any unique properties of TMZ, and theoretically, the differential effects of anti-IL-2R␣ mAbs during lymphopenia should hold true for other methods of lymphodepletion as well.
The anti-IL-2R␣ mAbs basiliximab and daclizumab are already used clinically as immunosuppressants. Although the adoptive transfer of T cells depleted of T Regs possess enhanced antitumor efficacy in lymphopenic animals, 42 T Regs may quickly regenerate, 43, 44 and a method to systemically deplete T Regs during successive rounds of chemotherapy, such as IL-2R␣-specific mAbs, would have high clinical applicability. 45 Thus, our cumulative preclinical and clinical data demonstrate that the administration of anti-IL-2R␣ mAbs during lymphopenia is not only a novel theoretical concept but also a broadly applicable and clinically relevant therapeutic modality for the potent enhancement of antitumor immunotherapy. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
